TetraLogic Announces Public Offering of Common Stock
April 30 2015 - 3:01PM
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a
clinical-stage biopharmaceutical company focused on discovering and
developing novel small molecule therapeutics in oncology and
infectious diseases, today announced that it has commenced an
underwritten public offering of shares of its common stock. All of
the shares in the offering are to be sold by TetraLogic.
William Blair & Company, L.L.C. and Nomura Securities
International, Inc. are joint book-running managers for the
offering. TetraLogic intends to grant the underwriters a
30-day option to purchase up to an additional 15 percent of the
share amount sold. The offering is subject to market
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
TetraLogic anticipates using the net proceeds from the offering
for general corporate purposes, including working capital,
continued development of its product candidate pipeline,
acquisitions and other business opportunities. The shares will
be issued by TetraLogic pursuant to a shelf registration statement
that was previously filed with, and declared effective by, the
Securities and Exchange Commission (SEC). A preliminary
prospectus supplement related to the offering has been filed with
the SEC and is available on the SEC's website located at
www.sec.gov. A final prospectus supplement related to the
offering will be filed with the SEC.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Any offer, if at all, will be made only by means
of a prospectus supplement and accompanying prospectus forming a
part of the effective registration statement, copies of which may
be obtained, when available, from William Blair & Company,
L.L.C., Attention: Prospectus Department, 222 West Adams
Street, Chicago, IL 60606, by telephone at (800) 621-0687, or by
e-mail at prospectus@williamblair.com; or from Nomura Securities
International, Inc., Attention: ECM Syndicate Department, 5th
floor, 309 West 49th Street, New York, New York 10019, by telephone
at (212) 667-9000, or by email at
equitysyndicateamericas@nomura.com.
Forward Looking Statements
Some of the statements in this release are forward looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. These statements relate to future
events or TetraLogic's pre-clinical and clinical development of
birinapant, SHAPE and other clinical programs, future expectations,
plans and prospects. Although TetraLogic believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. TetraLogic has attempted to
identify forward looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements
are only predictions and involve known and unknown risks,
uncertainties, and other factors, including those discussed under
the heading "Risk Factors" in our Annual Report on Form 10-K filed
with the SEC on February 26, 2015. Any forward-looking
statements contained in this release speak only as of its
date. We undertake no obligation to update any forward-looking
statements contained in this release to reflect events or
circumstances occurring after its date or to reflect the occurrence
of unanticipated events.
CONTACT: Pete A. Meyers
Chief Financial Officer and Treasurer
TetraLogic Pharmaceuticals Corporation
(610) 889-9900, x103
pete.meyers@tlog.com
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jun 2024 to Jul 2024
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jul 2023 to Jul 2024